<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is a cluster of factors contributing to increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but unifying mechanisms have not been identified </plain></SENT>
<SENT sid="1" pm="."><plain>Our aim was to study whether common variations in 17 genes previously associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> or components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and variants in nine genes with inconsistent association with at least two components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> would also predict future development of components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, individually or in combination </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Genetic variants were studied in a large prospective study of 16,143 non-diabetic individuals (mean follow-up time 23 years) from the Malm√∂ Preventive Project </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, development of at least three of <z:hpo ids='HP_0001513'>obesity</z:hpo> (BMI &gt;or= 30 kg/m(2)), <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> (triacylglycerol &gt;or= 1.7 mmol/l and/or <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering treatment), <z:hpo ids='HP_0000822'>hypertension</z:hpo> (blood pressure &gt;or= 140/90 mmHg and/or <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> medication) and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> (fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> &gt;or= 5.6 mmol/l and/or known <z:mp ids='MP_0002055'>diabetes</z:mp>) was defined as development of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The risk of developing at least three components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> or the individual components was calculated by logistic regression adjusted for age at baseline, follow-up time and sex </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Polymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> (p &lt; 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with <z:hpo ids='HP_0001513'>obesity</z:hpo> (p = 0.004) </plain></SENT>
<SENT sid="6" pm="."><plain>A polymorphism in the GCKR gene predicted <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> (rs1260326, OR 1.15, 95% CI 1.09-1.22, p &lt; 0.00001) but not the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>None of the studied polymorphisms was associated with more than two components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>A composite genotype score of the 17 polymorphisms associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> predicted the development of at least three components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (OR 1.04, p &lt; 0.00001) and the development of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> (OR 1.06, p &lt; 0.00001) </plain></SENT>
<SENT sid="9" pm="."><plain>Carriers of &gt;or=19 risk alleles had 51 and 72% increased risk of developing at least three components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, respectively, compared with carriers of &lt;or=12 risk alleles (p &lt; 0.00001 for both) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS/INTERPRETATION: Polymorphisms in susceptibility genes for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (TCF7L2, WFS1, IGF2BP2) and <z:hpo ids='HP_0001513'>obesity</z:hpo> (FTO) predispose to the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> by increasing the risk of one specific component of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The findings argue against a unifying genetic component for the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
</text></document>